Catalyst Pharmaceuticals (CPRX) concentration risks

The company's concentration profile is dominated by two high-share supplier dependencies, each tied to a separate product. For AGAMREE, the company has agreed to purchase commercial supply from Santhera while transitioning to its own direct supplier — a dependency that carries transition risk until the new supply chain is fully operational. For FYCOMPA, the company is committed to purchasing supplies from Eisai through at least the end of 2029, establishing a fixed-duration but meaningful counterparty dependency for a second revenue-generating product. Both exposures are dependency in character rather than structural: they reflect reliance on specific named suppliers under contractual arrangements, not an inherent feature of the market or manufacturing process. That distinction matters because a single supplier disruption — production shortfall, quality issue, regulatory action, or commercial dispute — could impair supply of the affected product without necessarily affecting the broader market. The two exposures are independent of each other, which provides some insulation at the portfolio level, but each is high-share on its own disclosed footprint. On balance, the most material near-term watch item is the pace and success of the transition away from Santhera for AGAMREE supply. Until that transition completes, the company remains reliant on a single external counterparty for its newest product's commercial supply chain.

For the engine’s reasoning on CPRX’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.